Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Selenium in Preventing Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Arizona
ClinicalTrials.gov Identifier:
NCT00978718
First received: September 16, 2009
Last updated: August 13, 2012
Last verified: August 2012

September 16, 2009
August 13, 2012
August 2001
June 2004   (final data collection date for primary outcome measure)
Incidence of biopsy-proven prostate cancer [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00978718 on ClinicalTrials.gov Archive Site
  • Rate of rise in serum PSA levels [ Designated as safety issue: No ]
  • Evidence of prostate cancer progression as assessed by levels of the serum markers alkaline phosphatase and Chromogranin A [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Selenium in Preventing Prostate Cancer
Phase III Trial of Selenium for Prostate Cancer Prevention

RATIONALE: Selenium supplements may stop or delay the development of prostate cancer in patients at high risk of prostate cancer. It is not yet known which dose of selenium may be more effective in preventing prostate cancer.

PURPOSE: This randomized phase III trial is studying how well selenium works in preventing prostate cancer.

OBJECTIVES:

  • To determine whether selenium (Se) supplementation decreases the incidence of prostate cancer.
  • To determine whether Se supplementation inhibits the biochemical progression of prostate cancer.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
  • Arm II: Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
  • Arm III: Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.

Blood samples are collected at baseline, at randomization, and then semi-annually for laboratory and other testing. Tissue samples may also be collected for biomarker analysis. Patients complete an initial questionnaire and urological-symptoms questionnaire at baseline, a follow-up questionnaire after randomization (to capture new illness, medications, and toxicity symptoms during the 30-day run-in period; a urological-symptoms questionnaire; a food-frequency questionnaire; and a mood questionnaire). Patients then undergo questionnaires semi-annually, including vital status, tablet compliance, nutrition, mood, new illnesses or medications, and any incidence of cancer or family history of cancer).

Interventional
Phase 3
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention
Prostate Cancer
  • Dietary Supplement: high-selenium baker's yeast
    Given orally
    Other Name: selenium
  • Dietary Supplement: selenium
    Given orally
  • Other: placebo
    Given orally
  • Placebo Comparator: Arm I
    Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
    Intervention: Other: placebo
  • Experimental: Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily
    Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
    Intervention: Dietary Supplement: selenium
  • Experimental: Arm III: 400 μg Se as high-Se baker's yeast daily
    Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
    Intervention: Dietary Supplement: high-selenium baker's yeast
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
700
June 2004
June 2004   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Clinical indicators consistent with the community standards of medical care that would justify a biopsy of the prostate for the diagnosis of cancer, including ≥ 1 of the following:

    • PSA level above the absolute value of 4 ng/mL or above a published age-ethnic adjusted PSA level appropriate for the community
    • Rising PSA that should represent a clinically significant PSA velocity (e.g., an estimated annual change in the PSA velocity ≥ 0.75 ng/mL)
    • Abnormal digital rectal examination of the prostate that identifies a clinically significant change in the prostate (e.g., a prostate nodule or a change in the firmness of the prostate)
    • Documentation of the clinical assessment that justified the prostate biopsy that allows classification of the patient to high-risk groups
  • Prostate biopsy negative for cancer within the past 12 months
  • Prostate biopsy negative for high-grade prostatic intraepithelial neoplasia (PIN)

    • PIN allowed provided it is grade 1

PATIENT CHARACTERISTICS:

  • Creatinine < 2 times upper limit of normal (ULN)
  • Bilirubin < 2 times ULN
  • SGOT and SGPT < 2 times ULN
  • Alkaline phosphatase < 2 times ULN
  • No history of a prior malignancy except for the following:

    • Adequately treated basal cell or squamous cell carcinoma
    • Adequately treated (i.e., complete surgical removal with negative margins) stage I cancer from which the patient is currently in complete remission
    • Any other cancer from which the patient has been disease-free for 5 years

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior systemic chemotherapy or radiotherapy
  • At least 90 days since prior and no other concurrent selenium > 55 μg/day as a dietary supplement (including multivitamin supplements)
  • More than 30 days since prior and no concurrent participation in any other clinical trial involving a medical, surgical, nutritional, or life-style intervention (e.g., dietary modifications, exercise)
Male
up to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00978718
01-0506-01, R01CA077789, P30CA023074, UARIZ-99-0045-01,
Not Provided
University of Arizona
University of Arizona
National Cancer Institute (NCI)
Principal Investigator: Frederick R. Ahmann, MD University of Arizona
University of Arizona
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP